Literature DB >> 17620742

Treatment of herpes simplex virus infection: rationale for occlusion.

Asha R Patel1, Paolo Romanelli, Brenda Roberts, Robert S Kirsner.   

Abstract

Orofacial herpes is a widespread benign malady that is also commonly known as herpes labialis or cold sores. Herpes of this type is generally caused by herpes simplex virus type 1 (HSV-1) and, to a lesser degree, herpes simplex virus type 2 (HSV-2), both of which are DNA viruses. The clinical presentation of herpetic lesions is normally located on mucocutaneous areas of the face and may eventually erode and ulcerate, leaving wounds that are known to be difficult to successfully treat. Focus of treatment has been related to treatment of the viral infection, and limited attention has focused on the resultant wounds. Clinical observation and recent histologic evaluation has demonstrated these wounds to extend through a disrupted cutaneous basement membrane into the dermis, suggesting that HSV is capable of causing partial-thickness wounds. This observation suggests a role for occlusion in the treatment of herpetic-induced partial-thickness wounds because occlusion is well recognized as the treatment of choice for other types of partial-thickness wounds.

Entities:  

Mesh:

Year:  2007        PMID: 17620742     DOI: 10.1097/01.ASW.0000280199.58260.62

Source DB:  PubMed          Journal:  Adv Skin Wound Care        ISSN: 1527-7941            Impact factor:   2.347


  8 in total

1.  HSV-1-induced SOCS-1 expression in keratinocytes: use of a SOCS-1 antagonist to block a novel mechanism of viral immune evasion.

Authors:  Kenneth G Frey; Chulbul M I Ahmed; Rea Dabelic; Lindsey D Jager; Ezra N Noon-Song; S Mohammad Haider; Howard M Johnson; Nancy J Bigley
Journal:  J Immunol       Date:  2009-06-19       Impact factor: 5.422

2.  Herpes simplex virus type 1 penetrates the basement membrane in human nasal respiratory mucosa.

Authors:  Sarah Glorieux; Claus Bachert; Herman W Favoreel; Annelies P Vandekerckhove; Lennert Steukers; Anamaria Rekecki; Wim Van den Broeck; Joline Goossens; Siska Croubels; Reginald F Clayton; Hans J Nauwynck
Journal:  PLoS One       Date:  2011-07-15       Impact factor: 3.240

3.  Reducing pain in acute herpes zoster with plain occlusive dressings: a case report.

Authors:  David A Keegan
Journal:  J Med Case Rep       Date:  2015-04-25

Review 4.  Improving the Care and Treatment of Monkeypox Patients in Low-Resource Settings: Applying Evidence from Contemporary Biomedical and Smallpox Biodefense Research.

Authors:  Mary G Reynolds; Andrea M McCollum; Beatrice Nguete; Robert Shongo Lushima; Brett W Petersen
Journal:  Viruses       Date:  2017-12-12       Impact factor: 5.048

5.  The effect of emodin, an anthraquinone derivative extracted from the roots of Rheum tanguticum, against herpes simplex virus in vitro and in vivo.

Authors:  Hai-Rong Xiong; Jun Luo; Wei Hou; Hong Xiao; Zhan-Qiu Yang
Journal:  J Ethnopharmacol       Date:  2010-11-02       Impact factor: 4.360

6.  Polymeric Electrospun Fibrous Dressings for Topical Co-delivery of Acyclovir and Omega-3 Fatty Acids.

Authors:  Tiago Costa; Artur Ribeiro; Raul Machado; Clarisse Ribeiro; Senentxu Lanceros-Mendez; Artur Cavaco-Paulo; Andreia Almeida; José das Neves; Marlene Lúcio; Teresa Viseu
Journal:  Front Bioeng Biotechnol       Date:  2019-12-03

7.  Herpes Zoster (Shingles) Patient-Centered Wound Outcomes: A Literature Review.

Authors:  Laura L Bolton; Nancy Faller; Robert S Kirsner
Journal:  Adv Skin Wound Care       Date:  2021-05-01       Impact factor: 2.373

8.  Low-dose Oral Thimerosal for the Treatment of Oral Herpes: Clinical Trial Results and Improved Outcome After Post-hoc Analysis.

Authors:  Stephen W Mamber; Thomas Hatch; Craig S Miller; John V Murray; Cynthia Strout; John McMichael
Journal:  J Evid Based Integr Med       Date:  2022 Jan-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.